<DOC>
	<DOCNO>NCT00586495</DOCNO>
	<brief_summary>Extension study 11515 ( NCT00661375 ) multicenter study sorafenib patient renal cell carcinoma ( RCC ) .</brief_summary>
	<brief_title>Long-term Extension From RCC Phase II ( 11515 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients classify two group transition date Study 11515 study . Population I : Patients willing continue study drug , investigator consider continuation study drug appropriate , meet criterion removal study Study 11515 end Study 11515 . Population II : Patients monitor survival status end Study 11515 . Population 1 1 . Patients willing continue study drug , 2 . Patients investigator consider continuation study drug appropriate 3 . Patients meet criterion removal study Study 11515 end Study 11515 . 4 . Patients give write informed consent prior study specific screen procedure understand patient right withdraw study time , without prejudice . Population 2 1 . Patients give write informed consent prior study specific screen procedure understand patient right withdraw study time , without prejudice . 1 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result 2 . Any condition could jeopardize safety patient affect his/her compliance study 3 . Pregnant breastfeeding patient . Both men woman enrol trial must use adequate birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Metastatic RCC</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Unresectable RCC</keyword>
</DOC>